pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·1d ago·1 min read
save

Regulators Discuss Plans to Streamline Europe’s Drug Approval Process at 2026 RAPS Convergence

Sep 29, 2026·read at raps ↗RegulatoryNeutral

A panel of European regulators gathered at the 2026 RAPS Convergence in Charlotte, North Carolina to discuss ongoing initiatives aimed at simplifying the continent’s regulatory framework.

The officials outlined plans to harmonize requirements across member states, cut redundant steps, and create more predictable timelines for drug developers.

By making the approval pathway more streamlined, the regulators hope to enable sponsors to bring new medicines to European patients faster and with greater certainty.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “Convergence: Regulators highlight efforts to streamline the European regulatory framework”

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Approval

related stories

  • Apr 28Rocket's PRV goes for $180M; Oruka targets $500M offeringEndpoints
  • Apr 28STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data neededSTAT
  • Apr 28FDA claims trial 'manipulation' tainted approval of ChemoCentryx drugEndpoints
  • Apr 28Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.BioPharma Dive
  • Apr 27Veradermics soars on positive data for baldness treatmentBioPharma Dive